Spedding M
Br J Pharmacol. 1984 Sep;83(1):211-20. doi: 10.1111/j.1476-5381.1984.tb10137.x.
Sodium salicylate (5-10 mM) has been used to distinguish the effects of the three calcium-antagonist subgroups which had been previously differentiated in functional studies. Sodium salicylate (10 mM) reduced the antagonistic effects of verapamil and diltiazem on Ca2+-induced contractions of K+ (40 mM)-depolarized taenia preparations from the guinea-pig caecum. In contrast, salicylate had no effect on the potency of nifedipine and increased the inhibitory effects of cinnarizine and flunarizine. Sodium salicylate (10 mM) had little effect on Ca2+-induced contractions per se. In preparations pretreated with calcium-antagonists and recontracted with high concentrations of Ca2+, salicylate (5 mM) caused an additional contraction when the preparations had been pretreated with verapamil or diltiazem but had no effect in control or nifedipine-treated preparations. In contrast, salicylate relaxed Ca2+-induced contractions in tissues which had been pretreated with cinnarizine, flunarizine, pimozide, bepridil, fendiline, perhexiline and with the calmodulin antagonist W-7. The mechanism of action of salicylate was investigated. Inhibition of prostaglandin biosynthesis or of oxidative phosphorylation by salicylate was not responsible for these effects because indomethacin (28 microM) and 2,4-dinitrophenol (20 microM) did not differentiate between calcium antagonists. The effects of salicylate are ascribed to an increase in negative surface charge on the membrane because other agents changing surface charge (3,5-dichlorosalicylate, 0.3 mM; benzoate, 20 mM) have similar effects and their potency is dependent on their affinity for lipid membranes. Furthermore, salicylate increased the effectiveness of the cationic local anaesthetic, (+)-propranolol (100 microM), but did not change the effects of the neutral local anesthetic, benzocaine (1 mM). It is argued that salicylate increases the effectiveness of cinnarizine by increasing accumulation of this drug in the cell membrane or at intracellular sites whereas the reduced effectiveness of verapamil and diltiazem is secondary to a change in the state of the Ca2+ channel.
水杨酸钠(5 - 10 mM)已被用于区分先前在功能研究中已区分出的三个钙拮抗剂亚组的作用。水杨酸钠(10 mM)减弱了维拉帕米和地尔硫䓬对豚鼠盲肠K⁺(40 mM)去极化绦虫制剂中Ca²⁺诱导收缩的拮抗作用。相比之下,水杨酸盐对硝苯地平的效力没有影响,并且增强了桂利嗪和氟桂利嗪的抑制作用。水杨酸钠(10 mM)本身对Ca²⁺诱导的收缩几乎没有影响。在用钙拮抗剂预处理并再用高浓度Ca²⁺使其收缩的制剂中,当制剂用维拉帕米或地尔硫䓬预处理时,水杨酸盐(5 mM)会引起额外的收缩,但在对照或硝苯地平处理的制剂中没有作用。相反,水杨酸盐使在用桂利嗪、氟桂利嗪、匹莫齐特、苄普地尔、芬地林、哌克昔林和钙调蛋白拮抗剂W - 7预处理的组织中Ca²⁺诱导的收缩松弛。研究了水杨酸盐的作用机制。水杨酸盐对前列腺素生物合成或氧化磷酸化的抑制并非这些作用的原因,因为吲哚美辛(28 microM)和2,4 - 二硝基苯酚(20 microM)并未区分钙拮抗剂。水杨酸盐的作用归因于膜表面负电荷的增加,因为其他改变表面电荷的试剂(3,5 - 二氯水杨酸盐,0.3 mM;苯甲酸盐,20 mM)具有类似作用,并且它们的效力取决于它们对脂质膜的亲和力。此外,水杨酸盐增加了阳离子局部麻醉药(+) - 普萘洛尔(100 microM)的效力,但没有改变中性局部麻醉药苯佐卡因(1 mM)的作用。有人认为,水杨酸盐通过增加这种药物在细胞膜或细胞内位点的积累来提高桂利嗪的效力,而维拉帕米和地尔硫䓬效力的降低是Ca²⁺通道状态改变的继发结果。